Lucid Diagnostics Inc. stock is up 25% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.
Lucid Diagnostics Inc. focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux. The company was incorporated in 2018 and is based in New York, New York.